Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: May 3, 2026

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Development of replication-defective herpes simplex virus vectors.

D Krisky¹, P Marconi, W F Goins

¹Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, PA.

Methods in Molecular Medicine

|February 5, 2014

Summary

Developing novel gene therapy vectors is crucial for treating central nervous system (CNS) diseases. New strategies are needed to effectively deliver therapeutic genes to non-dividing neurons for improved genetic therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Novel Oncolytic Herpes Simplex Virus Design based on the Common Overexpression of microRNA-21 in Tumors.

Journal of gene therapy·2018

Same author

Effects of herpes simplex virus vectors encoding poreless TRPV1 or protein phosphatase 1α in a rat cystitis model induced by hydrogen peroxide.

Gene therapy·2017

Same author

Gene therapy-from small beginnings to where we are now.

Gene therapy·2017

Same author

MnSOD mediated by HSV vectors in the periaqueductal gray suppresses morphine withdrawal in rats.

Gene therapy·2017

Same author

Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread.

Gene therapy·2016

Same author

Moving toward a gene therapy for Huntington's disease.

Gene therapy·2015

Area of Science:

Neuroscience
Genetics
Molecular Biology

Background:

Many nervous system diseases stem from genetic defects.
Genetic therapies aim to correct these defects via gene transfer.
Current retroviral vectors are unsuitable for non-dividing central nervous system (CNS) neurons.

Purpose of the Study:

To address the limitations of current gene therapy vectors for CNS disorders.
To outline requirements for novel vectors capable of treating CNS diseases.

Main Methods:

Review of existing gene therapy approaches.
Identification of challenges in delivering genes to the CNS.
Defining criteria for effective CNS gene therapy vectors.

Main Results:

More Related Videos

Generating Recombinant Avian Herpesvirus Vectors with CRISPR/Cas9 Gene Editing

Generating Recombinant Avian Herpesvirus Vectors with CRISPR/Cas9 Gene Editing

Published on: January 7, 2019

Production of Replication-Defective Retrovirus by Transient Transfection of 293T cells

Production of Replication-Defective Retrovirus by Transient Transfection of 293T cells

Published on: December 4, 2007

Related Experiment Videos

Last Updated: May 3, 2026

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Generating Recombinant Avian Herpesvirus Vectors with CRISPR/Cas9 Gene Editing

Generating Recombinant Avian Herpesvirus Vectors with CRISPR/Cas9 Gene Editing

Published on: January 7, 2019

Production of Replication-Defective Retrovirus by Transient Transfection of 293T cells

Production of Replication-Defective Retrovirus by Transient Transfection of 293T cells

Published on: December 4, 2007

Retroviral vectors fail in postmitotic CNS neurons.
New strategies are required for gene delivery to non-dividing neurons.
Novel vectors must efficiently deliver genes, persist long-term, and regulate expression.

Conclusions:

Effective gene therapy for CNS diseases necessitates the development of advanced, non-integrating vectors.
These vectors must overcome the challenge of targeting terminally differentiated neurons.
Future research should focus on creating versatile vectors for diverse therapeutic needs in the CNS.